首页> 外国专利> EARLY PROSTATE CANCER ANTIGEN-2: A NOVEL SERUM SPECIFIC MARKER FOR PROSTATE CANCER DETECTION

EARLY PROSTATE CANCER ANTIGEN-2: A NOVEL SERUM SPECIFIC MARKER FOR PROSTATE CANCER DETECTION

机译:早期前列腺癌抗原2:新型血清特异性前列腺癌检测剂

摘要

Early Prostate Cancer Antigen-2 (EPCA-2) is a prostate cancer biomarker, newly identified via proteomics-based examination of alterations in nuclear structure. EPCA-2 shows a higher overall specificity than PSA. Thus, an immunoassay based on antibodies against an epitope of EPCA-2 more accurately differentiates between confined and non-confined disease than PSA or Gleason score.
机译:早期前列腺癌抗原2(EPCA-2)是一种前列腺癌生物标志物,通过基于蛋白质组学的核结构变化检查新发现。 EPCA-2的总体特异性高于PSA。因此,与PSA或Gleason评分相比,基于抗EPCA-2表位抗体的免疫分析可更准确地区分局限性疾病和非局限性疾病。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号